Sunday, 21st January 2018 00:17:44 GMT+0530
Ad Here

Thursday, 4 January 2018

Sphaera Pharma Pte. Ltd. licenses its oncology drug candidate SPR064 for treatment of Solid Tumors to Nuance Biotech Inc.

Sphaera Pharma Pte. Ltd., a Singapore based drug discovery and development company announces a licensing transaction with Nuance Biotech Inc. a Shanghai based corporation.

Nuance Biotech’s partnership with Sphaera Pharma will exploit the late preclinical stage asset SPR064 for the treatment of Solid Tumors in Chinese and select other markets. SPR064 is a New Chemical Entity that has been developed using Sphaera’s proprietary Drug Modification Technology (DMT®) platform and is likely to be developed under the 505(b)2 regulatory approval pathway. The program provides a cremaphor/liposomal free formulation of paclitaxel to deliver a far safer, more soluble and efficacious drug.

As part of the deal, Nuance Biotech will develop the product and will manufacture the API and formulate the product in China for sales in Greater China and South Africa.

“We are very excited to partner with Nuance Biotech for development of SPR064 for China and South Africa. This is our 3rd licensing transaction employing our proprietary DMT platform over the last 6 months and Sphaera will work actively with the team at Nuance to advance this product through clinical development stage” commented Dr. Sundeep Dugar, President/CEO, Sphaera Pharma.

Sphaera Pharma is a fully integrated drug discovery and development company catering to a wide variety of therapeutic areas with robust & innovative science and has presence in Singapore, US and India with multiple collaborations all across the globe.

Mark Lotter (CEO& Co-founder) of Nuance Biotech commented, “Nuance is excited at the prospect of working with Sphaera on this exciting asset. Paclitaxel remains one of the leading cytotoxic agents in China, specially the more recently developed liposomal formulations. We believe that this novel form of paclitaxel will allow for an expanded use of the compound in cancer and will allow for Nuance to bring a much needed highly quality, novel formulation to China. Recent changes to the regulatory framework would allow for the product to leverage global data with China data for an expedited entry into this key market”.

Nuance Biotech (Shanghai) Co. Ltd was founded in 2014 and is a leading China based biotech company focused on commercial, regulatory and development stage assets. The company strategy and approach allows for a highly scalable commercial and drug development model i.e. ability to run multiple initiatives.

Recent News